Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of CBD Oral Formulations
NCT03877991Phase 1Recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cannabidiol in pain (3 arms), sponsored by Hadassah Medical Organization. Primary endpoint: Pharmacokinetic parameters of CBD (AUC 0-24h, Tmax, Cmax). Started Feb 2024; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
pain
Beyond the preview
Go deeper on NCT03877991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877991.